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Effect of 3 to 5 Years of Scheduled CEA and CT Follow-up
to Detect Recurrence of Colorectal Cancer
The FACS Randomized Clinical Trial
John N. Primrose, MD, FRCS; Rafael Perera, DPhil; Alastair Gray, BA, PhD; Peter Rose, MD, FRCGP; Alice Fuller, BSc;
Andrea Corkhill, BN; Steve George, MD, FRCP; David Mant, FRCGP, FRCP, FMedSci; for the FACS Trial Investigators
IMPORTANCE Intensive follow-up after surgery for colorectal cancer is common practice but is
based on limited evidence.
OBJECTIVE To assess the effect of scheduled bloodmeasurement of carcinoembryonic
antigen (CEA) and computed tomography (CT) as follow-up to detect recurrent colorectal
cancer treatable with curative intent.
DESIGN, SETTING, AND PARTICIPANTS Randomized clinical trial in 39 National Health Service
hospitals in the United Kingdom; 1202 eligible participants were recruited between January
2003 and August 2009who had undergone curative surgery for primary colorectal cancer,
including adjuvant treatment if indicated, with no evidence of residual disease on
investigation.
INTERVENTIONS Participants were randomly assigned to 1 of 4 groups: CEA only (n = 300),
CT only (n = 299), CEA+CT (n = 302), or minimum follow-up (n = 301). Blood CEAwas
measured every 3months for 2 years, then every 6months for 3 years; CT scans of the chest,
abdomen, and pelvis were performed every 6months for 2 years, then annually for 3 years;
and theminimum follow-up group received follow-up if symptoms occurred.
MAIN OUTCOMES ANDMEASURES The primary outcomewas surgical treatment of recurrence
with curative intent; secondary outcomes weremortality (total and colorectal cancer), time
to detection of recurrence, and survival after treatment of recurrence with curative intent.
RESULTS After amean 4.4 (SD, 0.8) years of observation, cancer recurrencewas detected in
199 participants (16.6%; 95%CI, 14.5%-18.7%) overall; 71 of 1202 participants (5.9%; 95%CI,
4.6%-7.2%)were treated for recurrencewith curative intent, with little difference according to
Dukes staging (stage A, 5.1% [13/254]; stage B, 6.1% [34/553]; stage C, 6.2% [22/354]). Surgical
treatment of recurrencewith curative intent was 2.3% (7/301) in theminimum follow-up group,
6.7% (20/300) in the CEA group, 8% (24/299) in the CT group, and 6.6% (20/302) in the
CEA+CT group. Comparedwithminimum follow-up, the absolute difference in the percentage
of patients treatedwith curative intent in the CEA groupwas 4.4% (95%CI, 1.0%-7.9%;
adjusted odds ratio [OR], 3.00; 95%CI, 1.23-7.33), in the CT groupwas 5.7% (95%CI,
2.2%-9.5%; adjustedOR, 3.63; 95%CI, 1.51-8.69), and in the CEA+CT groupwas 4.3% (95%CI,
1.0%-7.9%; adjustedOR, 3.10; 95%CI, 1.10-8.71). The number of deathswas not significantly
different in the combined intensivemonitoring groups (CEA, CT, and CEA+CT; 18.2% [164/901])
vs theminimum follow-up group (15.9% [48/301]; difference, 2.3%; 95%CI, −2.6% to 7.1%).
CONCLUSIONS AND RELEVANCE Among patients who had undergone curative surgery for
primary colorectal cancer, intensive imaging or CEA screening each provided an increased
rate of surgical treatment of recurrence with curative intent compared with minimal
follow-up; there was no advantage in combining CEA and CT. If there is a survival advantage
to any strategy, it is likely to be small.
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C olorectalcancer isamajorcauseofmorbidityandmortal-ity. It is the thirdmost commoncancerworldwide,with1.24millioncasesreportedtotheInternationalAgencyfor
ResearchonCancerin2008.1Traditionally,patientswhohavehad
curative treatment for colorectal cancerundergo regularhospi-
tal follow-up for at least 5 years to detect recurrence. Although
locoregionalrelapseistraditionallyassociatedwithpoorprogno-
sis,specialistcentersarereportingimprovedcureratesforselected
patients with combined-mode treatment.2 Success in treating
metastatic recurrencehas also been increasing. Approximately
40%ofpatients survive5years after complete resectionof liver
metastases3andcomparable resultshavebeenreportedfor lung
metastases.4The likelihoodofsurvival is increased ifmetastatic
disease is treated before it becomes symptomatic.5
Sevenpublishedclinical trialshavecompareddifferent fol-
low-up regimens.6-12 Twosystematic reviews suggest anover-
all survival benefit associated with more intensive
follow-up.13,14 However, trial quality was modest, the esti-
mated effect on disease-specific survivalwas not statistically
significant, and themechanism bywhich the substantial sur-
vival benefits reported were achieved is unclear. Two
reviews13,14 concluded that the existing evidencebaseneeded
to be strengthenedbyhigh-quality trials addressing the effec-
tiveness of the individual components of follow-up.
The2 individual componentsof follow-uprecognized tobe
widelyavailable andaffordableand tohave thepotential tode-
tect isolated metastatic recurrence at an early and surgically
treatable stage are computed tomography (CT) imaging of the
chest, abdomen, and pelvis and regular blood carcinoembry-
onicantigen(CEA)measurement.TheFACS(Follow-upAfterCo-
lorectal Surgery) trialwascommissionedby theUKNational In-
stitute for Health Research Health Technology Assessment
program to assess the effect of these 2 modes with the inten-
tionofprovidinga soundevidencebase to informclinical prac-
tice. The original intention was to conduct a trial of sufficient
size to assess survival advantage but when this proved infea-
sible, detectionof recurrence thatwas treatable surgicallywith
curative intentwas chosenas themainoutcomemeasure. Pre-
trial modeling suggested that unless follow-up increased the
numberofsuchrecurrencesdetected,an importantsurvivalad-
vantage of follow-upwould not be achieved.
Methods
Trial Design
TheFACS trialwas a factorial 2×2pragmatic randomized clini-
cal trial conducted in 39 centers in the United Kingdom; par-
ticipants were randomized independently to CT imaging ev-
ery 6 to 12 months or minimum follow-up and to CEA testing
every 3 to 6 months or minimum follow-up.
Participants
Toenroll in the trial, all participantshad tohaveundergonecu-
rative treatment for primary colorectal cancerwithno residual
disease,microscopically clearmargins, andDukes stage A to C
(TNM stage 1-3). Patients were disease-free based on colonic
imagingwith no evidence ofmetastatic disease (confirmed by
CTormagnetic resonance imaging liver scanandchestCTscan)
andwith a postoperative bloodCEA level of 10 μg/L or less fol-
lowingsurgeryor completionof adjuvant therapyas indicated.
Patients were excluded if they had concurrent serious ill-
nessordominantly inheritedcoloncancer,wereunable topro-
vide written informed consent, or were involved in a primary
treatment trialwithconflicting follow-uprequirements.Poten-
tial participants younger than 50 years ormore than 6months
from completion of primary or adjuvant treatment were in-
cluded only if agreed on by the chief surgical investigator.
All participants gavewritten informed consent to partici-
pate in the trial. Ethical approval for the trial was granted by
the National Health Service (NHS) South-West Research Eth-
ics Committee.
Study Setting
Participants were recruited at 39 NHS hospitals in the United
Kingdomwith access tohigh-volume regional services geared
to offer surgical treatment for recurrence.
Interventions
Follow-upwas scheduled to occur for 5 years after trial entry.
The factorial design, with independent allocation to the CEA
andCT interventions,meant thatpatients received 1of4 types
of follow-up:
1. CEA follow-up:measurement of bloodCEAevery 3months
for 2 years, then every 6 months for 3 years, with a single
chest, abdomen, andpelvis CT scan at 12 to 18months if re-
quested at study entry by hospital clinician
2. CT follow-up: CT of the chest, abdomen, and pelvis every
6 months for 2 years, then annually for 3 years
3. CEA and CT follow-up: both blood CEA measurement and
CT imaging as above
4. Minimumfollow-up:noscheduled follow-upexcepta single
CTscanof thechest, abdomen, andpelvis at 12 to 18months
if requested at study entry by the hospital clinician
All patients had undergone colonoscopy at trial entry to
ensure therewasno residual intraluminaldisease andwereof-
feredanend-of-trial colonoscopyat 5years; in the2CTgroups,
an additional colonoscopy was undertaken at 2 years.
Bloodcollectionkitsweresentdirectlytopatients,whothen
attended theirowngeneralpractice forphlebotomy.Bloodwas
sent to the biochemistry laboratory at the John Radcliffe Hos-
pital,Oxford; theCEAanalysiswasperformedusing aSiemens
Centaur XP analyzer. If a patient’s blood CEA level was 7 μg/L
or more above the level at trial entry, the test was repeated as
soon as possible; if the second test resultwas also greater than
this threshold, thepatient’sgeneralpracticephysicianwasasked
to refer the patient urgently to the local hospital.
Outcomes
The primary outcome was surgical treatment of recurrence
with curative intent after a minimum of 3 years of follow-up.
Secondary outcomesweremortality (total deaths and deaths
due to colorectal cancer), time todetectionof recurrence, and
survival after treatment of recurrence with curative intent.
Information on participant deathswas collected at the Of-
fice forNational Statistics central registry (all patientswere reg-
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isteredtohavethetrialsunitnotified intheeventof thepatient’s
death); cause of death was abstracted from death certificates.
Data on treatment of recurrence and treatment intentwere re-
cordedon case report forms by localNational Cancer Research
Network staff who had access to the full clinical records.
Randomization and Blinding
Randomizationto1of4groups(Figure1)ona1:1:1:1ratiowasper-
formedcentrally at theOxfordClinicalTrialsUnitusingamini-
mizationalgorithmtobalancepatientcharacteristicswithineach
centerbasedon3variables:adjuvantchemotherapy,sex,andage
group.Studynursescontacted theOxfordClinicalTrialsUnitby
telephonetoenterapatient inthetrial, reportingtherelevantpa-
tientcharacteristics; theywerethentoldthetrialgrouptowhich
the patient had been allocated.
Because thiswasapragmaticopen trial, itwasnotpossible
toconceal theallocationgroup fromeitherparticipantsor clini-
cians.However, theresearchstaffwhoabstractedoutcomedata
fromclinicalnoteswereemployedby the localNationalCancer
ResearchNetwork teams independentof the investigators.The
analysis programwasundertaken first using dummyvariables
for the allocationgroups and the codewasnot brokenuntil the
precise procedures for analysiswere agreed on.
Sample Size
Fromtherun-inphaseof thetrial, itwaspredictedthat2%ofpa-
tientsintheminimalfollow-upgroupwouldhaveundergonesur-
gery for recurrencewithcurative intentby3yearsof follow-up.
Itwas thereforeestimated thatasamplesizeof590participants
wouldneedtobeallocatedtoeachfactorialgrouptoachieve80%
powerwitha2-sidedα=.05todetectaminimum3%absoluteef-
fectof intensivemonitoringwithCTorCEA.Modelingsuggested
thata3%difference in treatmentwithcurative intent translated
intooverallsurvivalwasthesmallestdifferencethatwouldprove
costeffective.Tocomparetheminimuminterventiongroupwith
eachof theCEA,CT,andCEA+CTgroupsseparately, this sample
sizewouldprovide51%,70%,and84%power todetectabsolute
differencesof3%,4%,and5%,respectively.Wethereforedecided
to stop recruitmentwhen the sample size reached aminimum
of 1180 participants.
Statistical Analysis
Theprimaryanalysiswasanintention-to-treatcomparisonofthe
proportionofpatientsexperiencingrecurrencewhoweretreated
surgicallywithcurative intent (1)comparingallpatientsrandom-
ized to the3 intensive follow-upgroups (CEAonly,CTonly, and
CEA+CT)with theminimumfollow-upgroupand(2)comparing
allpatients randomizedto the2 factorial groups (CEAvsnoCEA
andCTvsnoCT).When feasible, crudedata arepresentedwith
statisticalcomparisonmadebetweenrandomizationgroupsbased
onχ2 tests for binary or categorical data, the t test or analysis of
variance as appropriate for comparing group means, and the
Kruskal-Wallis test for comparingmedians.
Time to recurrence was analyzed by the Kaplan-Meier
methodtotakeaccountofbothtimecensoringandthedifference
in thenumberof recurrencesdetected ineachgroup(ie, acrude
comparisonoftimetorecurrencemaybemisleadingbecausethis
approachdoesnottakeintoaccountrecurrencesnotyetdetected
inless-effectivefollow-upgroups).Theplotsoftimetorecurrence
were compared by the log-rank Mantel-Cox statistic. Adjusted
odds ratios for themain outcomewere calculated by binary lo-
gisticregression,enteringall thebaselinecharacteristicsreported
inTable 1 into themodel.For thecomparisonof factorial groups
(CEAvsminimumfollow-upandCTvsminimumfollow-up),an
interactionterm(CEAfactor×CTfactor)wasalsoentered.Weset
astatisticalsignificancethresholdofα=.05basedon2-sidedtests.
The analyseswere conducted using IBMSPSS version 20.
Protocol Adherence and Amendments
AdherencetoprotocolwasascertainedthroughNHShospitaland
laboratory records.Asecondaryper-protocol analysiswascon-
ductedexcludingpatientswhoreceivedanyunscheduledinves-
tigationorhadmissedmorethan1scheduledexamination.There
were 2 significant amendments to the original protocol during
Figure 1. Participant Flow
103 Deviated from protocol 101 Deviated from protocol47 Deviated from protocol 57 Deviated from protocol
300 Included in primary analysis
197 Included in per-protocol analysis
301 Included in primary analysis
200 Included in per-protocol analysis
302 Included in primary analysis
245 Included in per-protocol analysis
299 Included in primary analysis
252 Included in per-protocol analysis
302 Randomized to receive CEA 
follow-up
300 Received CEA as randomized
2 Excluded (residual disease
found)
304 Randomized to receive minimum
follow-up
301 Received minimum follow-up
as randomized
3 Excluded
1 Enrolled in conflicting
trial
2 Residual disease found
303 Randomized to receive CEA+CT
follow-up
302 Received CEA+CT as
randomized
1 Excluded (withdrew
consent)
302 Randomized to receive CT
follow-up
299 Received CT as randomized
3 Excluded (residual disease
found)
1211 Patients treated for primary
colon cancer randomized
Itwasnot feasible to collect informationon thenumberof potentially eligible pa-
tients excluded fromthe trial. For theprimary intention-to-treat analysis,mortality
datawere available through theNHScentral registry for all participants; thepoten-
tial completeness of ascertainmentof recurrence is reported inTable 2. For the
per-protocol analysis, details of thedeviations fromthe follow-up intervention re-
sulting in exclusion are given in eTable 1 in theSupplement.
CEA and CT to Detect Colorectal Cancer Recurrence Original Investigation Research
jama.com JAMA January 15, 2014 Volume 311, Number 3 265
Downloaded From: http://jamanetwork.com/pdfaccess.ashx?url=/data/journals/jama/929670/ by a University of Nottingham User  on 01/31/2017
Copyright 2014 American Medical Association. All rights reserved.
the trial. The initial protocol did not specify the single CT at 12
to18months in theminimumfollow-upandCEAgroups;66pa-
tients had been randomized to theminimum follow-up group
before this change took effect inMay 2005. Surgical treatment
withcurative intent rather thanoverall survivalwasspecifiedas
themain outcome in 2007when it became clear that we could
not recruit thenumberofparticipantsnecessary toestimatean
effect on overall survival with adequate statistical power.
Results
Characteristics of Participants
Allocation of the 1202 eligible participants recruited between
January 2003andAugust 2009 toeach randomizationgroup is
shown inFigure 1.The follow-up intervention lasted5yearsor,
for patients recruited afterAugust 2007, until August 31, 2012.
Characteristics at trial entryare shown inTable 1.Themeanage
ofparticipantswas69years, 736 (61.2%)weremale, 350 (29.1%)
hadsignificantcomorbidity;487 (40.5%)hadreceivedadjuvant
chemotherapy and 139 (11.6%) preoperative radiotherapy (for
rectalcancer)beforerandomization.Therandomizationmethod
was successful in achieving a good balance between random-
ization groups and factorial comparison groups. Cumulative
overall survival by stage and randomization group are shown
in eFigures 1 and 2, respectively, in the Supplement.
Detection of Recurrence
During theperiodofobservation for recurrence (mean,4.4 [SD,
0.8] years), cancer recurrence was detected in 199 partici-
pants (16.6%; 95% CI, 14.5%-18.7%); 41 (3.4%) had locore-
gional recurrence only and 101 (8.4%) hadmetastatic disease
limitedtothe lungand/or liver (Table2).TheKaplan-Meierplots
in Figure 2 show that the 3 intensive interventions tended to
detect recurrence earlier, although these differences in ear-
lier detectionwere not statistically significant. Therewere no
recurrences treatablewithcurative intentdetected in themini-
mum follow-up group after year 2. Two-thirds of recurrences
(n=130[65.3%;95%CI,58.7%-71.9%])weredetectedbyasched-
uledfollow-upinvestigation; theremainderwere intervalcases,
presenting symptomatically or incidentally during investiga-
tionof concurrent illness. Three luminal recurrenceswerede-
tected by the 2-year colonoscopy in the groups monitored by
CT imaging.Additionally, 3 cancersweredetectedby the5-year
colonoscopybut thesewerenewcancersandnot recurrentdis-
ease. The way in which the recurrences were treated is de-
tailed in eTable 1 in the Supplement.
Curative Treatment and Survival
The proportion of participants with recurrence surgically
treatedwith curative intent was 5.9% (71/1202; 95% CI, 4.6%-
7.2%) overall, with little difference between participants ac-
cording to Dukes staging (stage A, 5.1% [13/254]; stage B, 6.1%
Table 1. Characteristics of Participants at Trial Entry by Randomization Group and Factorial Group
Characteristics
Individual Randomization Group Factorial Comparison Group
CEA Only
(n=300)
CT Only
(n=299)
CEA+CT
(n=302)
Minimum
Follow-up
(n=301)
CEA
(n=602)
No CEA
(n=600)
CT
(n=601)
No CT
(n=601)
Age, y
Mean (SD) 68.8 (8.3) 69.0 (8.9) 69.5 (8.1) 69.3 (8.5) 69.2 (8.2) 69.1 (8.7) 69.2 (8.5) 69.1 (8.4)
Median (IQR) 69 (63-75) 69 (62-76) 70 (64-76) 70 (63-75) 69 (63-75) 70 (63-76) 70 (63-76) 69 (63-75)
Male, No. (%) 184 (61.3) 183 (61.2) 185 (61.3) 184 (61.1) 369 (61.3) 367 (61.2) 368 (61.2) 368 (61.2)
Concurrent treatment for
other illness, No. (%)
90 (30.0) 81 (27.1) 86 (28.5) 93 (30.9) 176 (29.2) 174 (29.0) 167 (27.8) 183 (30.4)
Pretreated with
chemotherapy, No. (%)
121 (40.3) 118 (39.5) 125 (41.4) 123 (40.9) 246 (40.9) 241 (40.2) 243(40.4) 244 (40.6)
Pretreated with radiotherapy,
No. (%)
32 (10.7) 34 (11.5) 38 (12.8) 35 (11.7) 70 (11.7) 69 (11.6) 72 (12.1) 67 (11.2)
Site of cancer, No. (%)a (n=293) (n=290) (n=292) (n=295) (n=585) (n=585) (n=582) (n=588)
Right colon 93 (31.7) 96 (33.1) 90 (30.8) 103 (34.9) 183 (31.3) 199 (34.0) 186 (32.0) 196 (33.3)
Left colon 118 (40.3) 96 (33.1) 110 (37.7) 105 (35.6) 228 (39.0) 201 (34.4) 206 (35.4) 223 (37.9)
Rectum 82 (28.0) 98 (33.8) 92 (31.5) 87 (29.5) 174 (29.7) 185 (31.6) 190 (32.6) 169 (28.7)
Dukes stage, No. (%)b (n=289) (n=293) (n=287) (n=292) (n=576) (n=585) (n=580) (n=581)
A 54 (18.7) 71 (24.2) 60 (20.9) 69 (23.6) 114 (19.8) 140 (23.9) 131 (22.6) 123 (21.2)
B 144 (49.8) 132 (45.1) 146 (50.9) 131 (44.9) 290 (50.3) 263 (45.0) 278 (47.9) 275 (47.3)
C 91 (31.5) 90 (30.7) 81 (28.2) 92 (31.5) 172 (29.9) 182 (31.1) 171 (29.5) 183 (31.5)
Smoking status, No. (%)c (n=290) (n=288) (n=294) (n=290) (n=584) (n=578) (n=582) (n=580)
Current smoker 20 (6.9) 16 (5.6) 18 (6.1) 14 (4.8) 38 (6.5) 30 (5.2) 34 (5.8) 34 (5.9)
Ex-smoker 145 (50.0) 154 (53.5) 162 (55.1) 155 (53.4) 307 (52.6) 309 (53.5) 316 (54.3) 300 (51.7)
Never smoker 125 (43.1) 118 (41.0) 114 (38.8) 121 (41.7) 239 (40.9) 239 (41.3) 232 (39.9) 246 (42.4)
Abbreviations: CEA, carcinoembryonic antigen; CT, computed tomography;
IQR, interquartile range.
a Site not specified precisely for 32 participants (2.7%).
bDukes stage not recorded for 41 participants (3.4%). Dukes stage is a measure
of the extent of the tumor. Dukes stage A indicates the cancer is only in the
innermost lining of the colon or rectum or slightly growing into themuscle
layer; Dukes stage B indicates the cancer has grown through themuscle layer
of the colon or rectum; and Dukes stage C indicates the cancer has spread to at
least 1 lymph node in the area close to the bowel.
c Smoking status not recorded for 40 participants (3.3%).
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[34/553]; stage C, 6.2% [22/354]). Table 3 shows that surgical
treatmentof recurrencewithcurative intentwashigher ineach
of the 3 more intensive follow-up groups compared with the
minimum follow-up group (absolute difference ranged from
4.3% to 5.7%; overall P = .02). The adjusted odds ratios were
3.0 (95% CI, 1.2-7.3) for CEA only and 3.6 (95% CI, 1.5-8.7) for
CT only. The odds ratio for the combined CEA+CT group was
similar to that for CTorCEAalone, providingnoevidence that
anyadditive effect is achievedbyusingboth together. The fac-
torial comparison showedanabsolutedifferencebetween the
intervention and comparison groups of 1.4% (95% CI, −1.2%
to 4.1%) for CEA and 2.8% (95% CI, 0.2%-5.5%) for CT.
Of the71participants treatedsurgicallywithcurative intent,
30alsoreceivedchemotherapy(7withradiotherapy).Ofthesepa-
tients,47 (69%;95%CI, 56.9%-79.5%)werestill aliveat the time
offollow-up(median,4.4yearsafterdiagnosisofrecurrence).The
absolutedifference intheproportionofpatients treatedandsur-
viving comparedwith theminimumfollow-up groupwas 3.3%
(95%CI, 0.5%-6.2%) for CEA, 2.0% (95%CI, −0.6% to 4.6%) for
CT, and 3.6% (95%CI, 0.7%-6.5%) for CEA+CT (overall P = .09).
The differences in the factorial comparisonwere 2.4% (95%CI,
0.3%-4.7%) for CEA and 1.2% (95%CI, 1.0%-3.4%) for CT.
Thenumberofdeathswashigher butnot significantlydif-
ferent in themore intensive follow-up groups comparedwith
Figure 2. Time to Diagnosis of Recurrence by Randomization Group
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Table 2. Duration of Follow-up and Diagnosis of Recurrence by Randomization Group and Factorial Group
Individual Randomization Groups Factorial Comparison Groups
CEA Only
(n=300)
CT Only
(n=299)
CEA+CT
(n=302)
Minimum
Follow-up
(n=301)
P
Valuea
CEA
(n=602)
No CEA
(n=600)
P
Valuea
CT
(n=601)
No CT
(n=601)
P
Valuea
Duration of follow-up,
mean (SD), y
3.78 (1.53) 3.69 (1.59) 3.74 (1.58) 3.64 (1.69) .75 3.76 (1.55) 3.67 (1.64) .33 3.71 (1.59) 3.71 (1.61) .96
Less than full period of
observation, No. (%)b
41 (13.7) 39 (13.0) 46 (15.2) 61 (20.3) .61 87 (14.5) 100 (16.7) .29 85 (14.1) 102 (17.0) .18
Diagnosis of recurrence,
all sites, No. (%)
57 (19.0) 57 (19.1) 48 (15.9) 37 (12.3) .08 105 (17.4) 94 (15.7) .41 105 (17.5) 94 (15.6) .39
Liver and/or lung only 30 33 25 13 55 46 58 43
Locoregional only 12 12 11 6 23 18 23 18
Other metastatic 15 12 12 18 27 30 24 33
Recurrences detected by
scheduled follow-up ex-
amination, No. (%)
33 (11.0) 48 (16.1) 40 (13.2) 9 (3.0) <.001 73 (12.1) 57 (9.5) .14 88 (14.6) 42 (7.0) <.001
Blood CEA level 30 0 13 0 43 0 13 30
CT imaging 3 46 26 9 29 55 72 12
Colonoscopy 0 2 1 0 1 2 3 0
Abbreviations: CEA, carcinoembryonic antigen; CT, computed tomography.
a Reported P values are based on the Pearson χ2 test for binary comparisons,
1-way analysis of variance or independent t tests in comparing means.
b Participants who died during follow-up without evidence of recurrence
(n = 46), withdrew consent or moved fromNational Health Service to private
care (n = 24), developed another primary cancer (n = 36), or for whom case
report forms seeking information on recurrence had not been completed for
the entire period at risk (n = 78).
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theminimum follow-up group (18.2% [164/901] vs 15.9% [48/
301]; difference, 2.3%; 95%CI, −2.6% to 7.1%), aswas thenum-
ber of disease-specific colorectal cancer deaths (10.4% [94/
901] vs9.3% [28/301]; difference, 1.1%;95%CI, −2.7% to5.0%).
TheKaplan-Meier survival curvesby randomizationgroupand
Dukes stage are shown in eFigures 1 and 2 in the Supplement.
Adherence to Protocol
The extent of adherence to the follow-up protocol is shown in
eTable 2 in the Supplement. Patient adherence was very good,
with only 5.8% (35/602) in the CEA groupmissing more than 1
scheduled CEA test and 5.0% (30/601) in the CT groupmissing
morethan1CTscan.Althoughclinicianadherenceappears tobe
lower(10.6%ofparticipants[127/1202]receivedunscheduledCEA
bloodtests,10.6%[127/1202]unscheduledCTscans,and9.7%[117/
1202]unscheduledcolonoscopies), theprotocol required inves-
tigation of any patients presenting with symptoms between
scheduledfollow-uptests.Substantiallymoreunscheduledtests
wereperformed inpatientsnot receiving regularCTscans,with
16.5%(99/601)vs4.7%(28/601) receiving1ormoreunscheduled
CEAtests,17.6%(106/601)vs3.5%(21/601)receiving1ormoreun-
scheduledCTtests,and15.6%(94/601)vs3.8%(23/601) receiving
1 ormore unscheduled colonoscopies.
Per-Protocol Analysis
Theresultsofaper-protocolanalysisareshowninTable4,exclud-
ing the308patients (25.6%)whomissedmore than1 scheduled
visitorunderwentanyunscheduledinvestigation.Theresultsare
Table 4. Treatment of RecurrenceWith Curative Intent and Total Mortality by Randomization Group and Factorial Group (Per-Protocol Analysis)
Individual Randomization Groups Factorial Comparison Groups
CEA Only
(n=197)
CT Only
(n=252)
CEA+CT
(n=245)
Minimum
Follow-up
(n=200)
P
Value
CEA
(n=442)
No CEA
(n=452)
P
Value
CT
(n=497)
No CT
(n=397)
P
Value
Surgical treatment with
curative intent, No. (%)
15 (7.6) 24 (9.5) 18 (7.3) 3 (1.5) .007 33 (7.5) 27 (6.0) .37 42 (8.5) 18 (4.5) .02
Adjusted odds ratio
(95% CI)a
5.10
(1.43-18.2)
6.71
(1.96-22.9)
5.24
(1.50-18.3)
1
[Reference]
1.41
(0.40-5.04)
1
[Reference]
1.45
(0.41-5.06)
1
[Reference]
Wald P value .03 .005 .02 .60 .56
Surgical treatment with
curative intent and still
alive, No. (%)
10 (5.1) 11 (4.4) 14 (5.7) 3 (1.5) .15 24 (5.4) 14 (3.1) .08 25 (5.0) 13 (3.3) .20
Adjusted odds ratio
(95% CI)a
3.25
(0.83-12.7)
2.78
(0.74-10.5)
3.87
(1.05-14.3)
1
[Reference]
2.27
(0.53-9.62)
1
[Reference]
2.55
(0.61-10.7)
1
[Reference]
Wald P value .09 .13 .04 .27 .20
Total deaths, No. (%) 46 (23.4) 58 (23.0) 43 (17.6) 39 (19.5) .35 89 (20.1) 97 (21.5) .63 101 (20.3) 85 (21.4) .69
Deaths attributed to colo-
rectal cancer, No. (%)
28 (14.2) 33 (13.1) 26 (10.6) 24 (12.0) .69 54 (12.2) 57 (12.6) .86 59 (11.9) 52 (13.1) .58
Abbreviations: CEA, carcinoembryonic antigen; CT, computed tomography.
a The adjusted odds ratios and associated 95% CIs were estimated using logistic
regression, including all the baseline variables listed in Table 1 in themodel. For
the factorial group comparison, the odds ratio is also adjusted for interaction
with the other randomization factor (eg, the CEA×CT interaction). The
standard P values given for comparison of proportions are based on the χ2 test
for heterogeneity (which tests whether the overall distribution in proportions
could have occurred by chance). TheWald P values test whether the odds of
detecting recurrence in each of the intensive follow-up groups are significantly
different from that in theminimum follow-up group.
Table 3. Treatment of RecurrenceWith Curative Intent and Total Mortality by Randomization Group and Factorial Group (Intention-to-Treat Analysis)
Individual Randomization Groups Factorial Comparison Groups
CEA Only
(n=300)
CT Only
(n=299)
CEA+CT
(n=302)
Minimum
Follow-up
(n=301)
P
Value
CEA
(n=602)
No CEA
(n=600)
P
Value
CT
(n=601)
No CT
(n=601)
P
Value
Surgical treatment with
curative intent, No. (%)
20 (6.7) 24 (8.0) 20 (6.6) 7 (2.3) .02 40 (6.6) 31 (5.2) .28 44 (7.3) 27 (4.5) .04
Adjusted odds ratio
(95% CI)a
3.00
(1.23-7.33)
3.63
(1.51-8.69)
3.10
(1.27-7.57)
1
[Reference]
1.45
(0.45-4.65)
1.38
(0.43-4.36)
Wald P value .02 .004 .01 .53 .59
Surgical treatment with
curative intent and still
alive, No. (%)
15 (5.0) 11 (3.7) 16 (5.3) 5 (1.7) .09 31 (5.1) 16 (2.7) .03 27 (4.5) 20 (3.3) .30
Adjusted odds ratio
(95% CI)a
2.88
(1.02-8.14)
2.10
(0.72-6.15)
3.10
(1.10-8.71)
1
[Reference]
2.14
(0.58-7.84)
2.38
(0.64-8.84)
Wald P value .046 .18 .03 .25 .20
Total deaths, No. (%) 56 (18.7) 60 (20.1) 48 (15.9) 48 (15.9) .45 104 (17.3) 108 (18.0) .74 108 (18.0) 104 (17.3) .76
Deaths attributed to colo-
rectal cancer, No. (%)
32 (10.7) 35 (11.7) 27 (8.9) 28 (9.3) .66 59 (9.8) 63 (10.5) .69 62 (10.3) 60 (10.0) .85
Abbreviations: CEA, carcinoembryonic antigen; CT, computed tomography.
a The adjusted odds ratios and associated 95% CIs were estimated using logistic
regression including all the baseline variables listed in Table 1 in themodel. For
the factorial group comparison, the odds ratio is also adjusted for interaction
with the other randomization factor (eg, the CEA×CT interaction). The
standard P values based on the χ2 test for heterogeneity (which tests whether
the overall distribution in proportions could have occurred by chance). The
Wald P values test whether the odds of detecting recurrence in each of the
intensive follow-up groups are significantly different from that in theminimum
follow-up group.
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consistentwiththeintention-to-treatanalysisbuteffectestimates
arehigher: theabsolutedifferences in rateofdetectionof treat-
ablerecurrenceinthemoreintensivefollow-upgroupscompared
with theminimum follow-up groupwere 5.8% to 8.0%.
Discussion
The 2 follow-up tests assessed in this trial were CEA and CT
imaging.Meta-analyses have suggested that these are the only
modes with significant potential to detect curatively treatable
metastaticrecurrenceinpatientswithcolorectalcancer.13,14Clini-
calandultrasoundexaminationlacksensitivitywhereasmagnetic
resonanceimagingcanrealisticallybeappliedonlytotheliverand
lacksstrongevidenceofeffectivenessindetectingrecurrence.13,14
Computedtomography–positronemissiontomographywasnot
anavailabletechnologywhenthistrialwasinitiatedand,because
of cost and logistics,wouldbepreferred to standardCT for rou-
tine follow-uponly ifevidencesuggestedmuchsuperiorperfor-
mance.Endoscopic imaging (colonoscopy)wasprovided topa-
tients inall studygroupsbecause it isastandardevidence-based
elementof follow-upcare that candetectmetachronouspolyps
or cancer (and, rarely, intraluminal recurrence).15
Ourresultsshowthatintensivefollow-upbyeitherscheduled
CEAorCTincreasedthe likelihoodofdetectingarecurrencethat
canbetreatedwithcurativeintent.Theabsolutedifferenceinthe
proportion of participants treated with curative intent was ap-
proximately 5% in the intention-to-treat analysis and8% in the
per-protocolanalysis,suggestingthatbetween12and20patients
needtobefolloweduptoidentify1potentiallycurablerecurrence.
More than two-thirdsof thepatients treated surgicallywith cu-
rative intentwere still alive at amedian follow-upof just over 4
yearspostrecurrence,suggestingthat5-yearsurvivalmaybemore
than the 40%previously reported.3,4
Although theproportionof recurrences treatedwith cura-
tive intent (and the success of such treatment) is higher com-
pared with earlier reports, the absolute number of treatable
recurrencesdetected is lower.14This isnot explicablebydiffer-
ences instage-specific case-mix (detectionof recurrences treat-
ablewith curative intentwas similar irrespectiveof stage), nor
is there anyevidence thatparticipants in theFACS trialwere at
lowriskof recurrencewithinstage(84.5%ofstageCparticipants
hadreceivedadjuvantchemotherapy).Stage-specificoverallsur-
vival ofparticipants in this study (eFigure2 in theSupplement)
is comparable with that reported in trials of adjuvant chemo-
therapy, such as MOSAIC.16 A more likely explanation for the
lowerdetectionof treatable recurrence is the rigorof the inves-
tigativeproceduresundertaken toensure thatno residual can-
cerwaspresentat trialentry. Itsuggeststhatthehighrateofearly
recurrence reported from routine cancer statistics in England
andScandinavia17 reflects residualdiseasethatwouldhavebeen
detectedwithmore thorough imaging. Itprobablyalsoexplains
the greater benefit of intensive follow-up reported inprevious
trials—follow-updetectedresidualdisease,notrecurrence.Akey
findingof this study is therefore theneed to fully stagecolorec-
tal cancer before embarking on follow-up.
Thecomparisonbetweeninterventiongroupssuggests that
monitoring with CEA combined with a single CT scan at 12 to
18months isnot significantlydifferent fromundertaking regu-
lar CT scanning. Because CEA testing can be done in primary
care, it is likely to be more cost-effective than regular CT
imaging.However, imaging is still necessary to confirm recur-
rence, and in the combined CEA+CT group, two-thirds of re-
currences were first detected by CT. The diagnostic perfor-
mance of CEA as amonitoring test depends on the frequency
of testing and the algorithm used to interpret the result. The
algorithm applied in the FACS trial (refer for imaging if blood
CEA level is 7 μg/L above baseline) achieves good specificity
but at the cost ofmodest sensitivity.18 An ongoing study is in-
vestigatingwhether a higher sensitivity can be achieved at an
acceptable level of specificity by applying a diagnostic algo-
rithm that takes account of changeover time andhas been ap-
pliedsuccessfully in interpretingcancerantigen125 levelswhen
screening for ovarian cancer.19
Wehadplannedtoreportourresultsafterallparticipantshad
completed5yearsof follow-upbecauseearlyanalysis increases
the riskof lead-timebias.However, therehavebeennocasesof
recurrence treatablewith curative intent after 2yearsof follow-
up in theminimumfollow-upgroup,making lead-timebiasun-
likely inourmaincomparison.Nevertheless, subject tocontinu-
ing informed consent from those in the minimum follow-up
group,weplan tocontinue follow-upasplannedto increase the
precisionofourresults,particularly inrelationtodisease-specific
mortality andposttreatment survival.
The decision onwhether the absolute benefit of follow-up
is sufficient to justify its opportunity cost will differ between
health economies. The benefits of follow-up appear to be inde-
pendent of diagnostic stage (because although there are fewer
recurrenceswithbetter-stage tumors, theyaremore likely tobe
curable), suggestingthatstage-specific follow-upstrategiesmay
notbenecessary.However, thoroughstaging investigationat the
end of primary treatment to detect residual disease is still im-
portantbecausealargenumberof“recurrences”reportedinrou-
tine series are probably residual disease that should be de-
tected and treated before embarking on follow-up. Because of
the detailed investigation performed before trial entry to ex-
clude residual disease, our results alsoprovidedata on the tim-
ingofrecurrencethatcanstrengthentheevidencebaseforchoos-
ing theoptimal frequencyof testing.Duplicationofmonitoring
testsdoesnotappeartoaddvalue;participants intheCEAgroups
hada singleCTat 12 to 18months,when3 recurrenceswerede-
tected, but otherwise there was no suggestion of benefit from
monitoringwith both CEA and CT.
Thesizeof the trialprovides limitedprecision inestimating
survival.Withanobserved15.9%mortality rate in theminimum
follow-upgroup,wehadonly31%power (with2-sidedα=.05) to
detecta5%effectonsurvival.Althoughtheobserved2%aggre-
gatesurvivaladvantageof theminimumfollow-upgroupvs the
moreintensivefollow-upgroupsisunlikelytobeduetobias(cen-
tral death registration in the United Kingdommeans therewas
no loss to follow-up), it couldbedue tochance.Anobservedab-
solute6% increase in surgerywith curative intentpredicts a 2%
to3%survivaladvantagewithintensivefollow-up.Theconfidence
intervals aroundboth the totalmortalityandcolorectal cancer–
specificmortality rates indicate that our results are still consis-
tentwith this outcome.
CEA and CT to Detect Colorectal Cancer Recurrence Original Investigation Research
jama.com JAMA January 15, 2014 Volume 311, Number 3 269
Downloaded From: http://jamanetwork.com/pdfaccess.ashx?url=/data/journals/jama/929670/ by a University of Nottingham User  on 01/31/2017
Copyright 2014 American Medical Association. All rights reserved.
Conclusions
Among patients who had undergone curative surgery for
primary colorectal cancer, intensive imaging and CEA
screening each provided an improved rate of recurrence
treated with curative intent compared with minimal follow-
up; there was no advantage to combining both strategies. If
there is a survival advantage to any strategy, it is likely to be
small.
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